Plain-English translation of NCT05338931 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing AT101, a new type of therapy that uses your own immune cells to fight a type of blood cancer called B-cell non-Hodgkin's lymphoma. The treatment works by removing some of your immune cells, engineering them in a laboratory to recognize and attack cancer cells, and then returning them to your body. The researchers want to find the right dose of this treatment and learn how safe and effective it is.
Many people with aggressive B-cell lymphomas run out of standard treatment options because their cancer stops responding to chemotherapy or they can't tolerate it. This medication represents a new approach that may help patients who have few other choices.
You likely qualify if…
You likely don't qualify if…
You will have your own immune cells collected through a procedure, sent to a laboratory to be modified, and then reinfused back into your body. The study involves multiple visits to the research center for medical exams, blood tests, and monitoring to watch how you respond to the treatment and manage any side effects. The entire trial may last several months as researchers track both the safety of this treatment and whether it helps control your cancer.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
South Korea
Phase
Safety & dosing / Early efficacy
Sponsor
AbClon
Enrollment target
~82 participants
Started
March 2022
Primary completion
March 2030
Age range
19 Years and older
Last updated on clinicaltrials.gov in May 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Young ha Lee
Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.